New Blood Test Quickly Predicts Ibrance Treatment Response in Breast Cancer Patients, Study Shows

New Blood Test Quickly Predicts Ibrance Treatment Response in Breast Cancer Patients, Study Shows
A new blood test could predict how a patient will respond to metastatic breast cancer medication Ibrance (palbociclib) months earlier than current approaches, a U.K. study suggests. Research shows the test could provide a reliable prediction as early as two to three weeks after starting treatment. However, scientists caution the results still need to be replicated before the test is used clinically. The study, “Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer,” was published in the journal Nature Communications. "[Ibrance] is one of a new class of drugs that delays cancer progression for patients with advanced breast cancer, but it's not effective for everybody. The problem is we have to wait for two to three months before doing a scan to see if the therapy is working,” Nicholas Turner, MD, PhD, the study’s senior author and a professor at The Institute of Cancer Research in London, said in a press release. “Having an early indication of how likely a treatment is to work might allow us to adapt treatment — switching some patients to an alternative drug that is more likely to benefit them," he said. The test detects DNA mutations in breast cancer patients by analyzing fragments of circulating tumor DNA (ctDNA), which refers to cancer DNA that has entered the bloodstream. Researchers evaluated the te
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.